April 20th, 2005. Asbestos and mesothelioma: worldwide trends
S. , the UK and Australia will be reproduced in the developing world.
April 15th, 2005. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study
9). Our results suggest that SV40 increases the risk of MM among individuals exposed to asbestos.
Conclusions: PSC in malignant pleural mesothelioma was significantly associated with prolonged survival. It is not known whether the reduced risk of death was associated with PSC or whether patients who had prolonged survival tended to receive more PSC. The pemetrexed plus cisplatin treatment group had a statistically significant survival advantage even though fewer patients from that arm of the trial received PSC. The potentially beneficial role of PSC should be assessed in prospective trials.
April 7th, 2005. Epidemic of mesothelioma in Egypt
The use of EGFR inhibitors may have a role in the treatment of MM. Asbestos in Cairo is a silent killer and measures toward eliminating it entirely or at least strictly controlling human contact with this dangerous carcinogen have to be taken in order to combat the coming epidemic of mesothelioma in Egypt.
This combined modality approach is feasible for locally advanced MPM, and initial analysis suggests improved resectability. This experience supports additional studies of induction and multimodality therapy, especially with regimens such as cisplatin and pemetrexed which may be better tolerated and more effective.
April 1st, 2005. Mesothelioma of the tunica vaginalis testis: report of 2 cases with asbestos occupational exposure
There is no evidence of recurrence at 2-year follow-up. The patient had been exposed to asbestos 52 years previously for a 5-year period.
April 1st, 2005. Pemetrexed-cisplatin combination in mesothelioma
These data led to the approval of the drug by the US Food and Drug Administration and recently by the European Medicines Evaluation Agency for this combination in malignant pleural mesothelioma, and consequently founded the first standard of treatment in this disease. This review reflects the development of chemotherapy in malignant pleural mesothelioma, discusses the results of the EMPHACIS trial, and outlines further developments for pemetrexed-containing regimens in malignant pleural mesothelioma.
April 1st, 2005. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma
It is concluded that, because of their high specificity and sensitivity for epithelioid mesotheliomas, D2-40 and podoplanin are very useful markers for the diagnosis of these tumors. When compared with the other markers that are currently available, in my opinion, they appear to be the best.
April 1st, 2005. An autopsy case of primary pericardial mesothelioma in arc cutter exposed to asbestos through talc pencils
Subsequent transmission electron microscopic examination equipped with an energy dispersive X-ray analyzer revealed that the fibers identified in the lungs were fibrous talc and actinolite. These findings suggested that this patient had been occupationally exposed to asbestos contaminated in the talc pencils, which induced the development of primary pericardial mesothelioma.
April 1st, 2005. Radiation Injury to the Liver After Intensity-Modulated Radiation Therapy in Patients with Mesothelioma: An Unusual CT Appearance
Conclusion: Abnormal hepatic enhancement after extrapleural pneumonectomy and IMRT is common in patients with mesothelioma. Knowledge of the early occurrence and typical location and appearance of IMRT-induced injury can be useful in preventing misinterpretation as metastatic disease or recurrent tumor.
- Home
- About Mes-Line
- Categories
- Contact Us
- Glossary
- Processor
Article Categories
- Full Archive
- Type of Assessment:
- Case Study
- Causation
- Diagnosis & Differentiation
- Epidemiological
- General
- Staging
- Survival
- Symptoms & Symptom Management
- Treatment
- Angiogenesis
- Chemotherapy
- Bevacizumab (Avastatin)
- Carboplatin
- Cisplatin (Platinol ®)
- Coramsine
- Cyclophosphamide
- Cycloplatam
- Docetaxel (Taxotere)
- Doxorubicin
- Epirubicin (Ellence)
- Erlotinib (Tarceva®)
- Gemcitabine (Gemzar)
- Imatinib Mesylate (Gleevec/Glivec)
- Irinotecan
- melphalan
- mitomycin-C
- Oxaliplatin (Eloxatin)
- Oxaliplatine
- paclitaxel
- Pemetrexed (Alimta)
- Raltitrexed (Tomudex)
- Ranpirnase (Onconase)
- Selenite
- Sunitinib
- Taurolidine
- Vinorelbine
- Determining Efficacy
- EGFR
- Gene Therapy
- Immune-based Therapies
- Intraperitoneal Chemotherapy
- Intrapleural Chemotherapy
- Kinase Inhibitors
- New & Novel
- Photodynamic Therapy (PDT)
- pleurodesis
- Radiation
- Radiofrequency Ablation
- Signal Transduction Inhibitors
- Surgery
- Trimodality Therapy
- Type of Mesothelioma:
Annual Archives:
-
You are currently browsing the Mesothelioma Journal Articles weblog archives for April, 2005.
